The UK and US have reached a landmark trade agreement that will guarantee zero import taxes on UK drug exports going into the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to increase funding on drugs through the NHS. This commitment secures that duties on these key exports will stay at nothing for a duration of three years.
This deal comes after earlier statements to significantly raise import taxes on patented pharmaceutical products, with increases mentioned as high as one hundred percent.
"This deal with the UK reinforces the international landscape for new treatments and introduces long-overdue fairness to American-British medicine commerce," a statement declared.
Economic Impact
Pharmaceuticals represent one of the UK's largest exports to the US, which is clearly the primary buyer for large British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This figure represented nearly one-fifth of total UK exports in that period.
"This guarantee secures work, increases capital expenditure and paves the way for the UK to become a worldwide center for life sciences," a minister stated.
Detailed UK Commitments
The pact entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it considers new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a aim to increase overall public funding on treatments from 0.3% of GDP to 0.6% over the next decade.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments topped 20%.
Industry Background
The deal takes place against a ongoing row between the sector and the UK government over drug pricing and NHS adoption.
These tensions were exacerbated by claims that American consumers were paying several times more for the identical medicines than people in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been paused or abandoned, while substantial expansions have been announced toward projects in the United States.
A senior figure stated that the NHS must invest a greater share on medicines, noting that its expenditure on drugs had shrunk as a share of its overall budget over the last ten years.
